Recurrent Meningococcal Disease: Pediatric Case | MDster You are offline Back online! [ MDster home ](/ "MDster home") Specialities [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) [ Features ](https://mdster.com/features) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) Menu Specialities [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) [ Features ](https://mdster.com/features) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) [ Login ](https://mdster.com/auth/login) 1. [ Home ](https://mdster.com) 2. [ Blog ](https://mdster.com/blog) 3. [ Case Discussion ](https://mdster.com/blog?category=case-discussion) 4. Recurrent Meningococcal Disease in Adolescents: A Case Discussion [ Case Discussion ](https://mdster.com/blog?category=case-discussion) Recurrent Meningococcal Disease in Adolescents: A Case Discussion =================================================================== Shock, complement deficiency, and prevention after a second invasive Neisseria episode [ MDster Editorial Team ](https://mdster.com/about) · Apr 21, 2026 · 6 min read · 31 [ Reviewed by Dr. Ali Ragab, MBBCH, MSc, MCAI ](https://mdster.com/medical-reviewers/dr-ali-ragab) [Editorial Policy](https://mdster.com/editorial-policy) | [Corrections Policy](https://mdster.com/corrections) [ Board Review ](https://mdster.com/blog?tag=board-review) [ Pediatrics ](https://mdster.com/blog?tag=pediatrics) [ Case Discussion ](https://mdster.com/blog?tag=case-discussion) [ Infectious Diseases ](https://mdster.com/blog?tag=infectious-diseases) [ Immunology ](https://mdster.com/blog?tag=immunology) ![Recurrent Meningococcal Disease in Adolescents: A Case Discussion](https://mdster.com/storage/blog/images/recurrent-meningococcal-disease-in-adolescents-a-case-discussion.jpg) Share this article Share this post Six hours after fever begins, the 17-year-old can still answer questions, which is exactly why meningococcal disease is treacherous: the window between compensated illness and shock can be short. In an adolescent with fever, headache, photophobia, nuchal rigidity, petechiae, and CSF showing Gram-negative diplococci, management must split immediately into two tracks—treat invasive meningococcal disease and explain why this is his second episode. Recurrent meningococcal disease should be treated as a host-defense problem until proven otherwise. [\[1\]](#cite-1 "Reference [1]") Why recurrence changes the differential --------------------------------------- The petechial rash and Gram stain make *Neisseria meningitidis* the leading diagnosis, but the recurrence reframes the case. NICE identifies primary or secondary immunodeficiency—especially congenital complement deficiency or acquired complement inhibition—as the key risk factor for recurrent meningococcal disease; HIV and absent splenic function also remain on the list. For recurrent bacterial meningitis more broadly, an anatomic defect such as a CSF leak matters, but recurrent invasive *Neisseria* should push complement testing much higher in the queue. [\[2\]](#cite-2 "Reference [2]") ClueHigh-yield inferenceSecond invasive *Neisseria* episodeScreen for complement deficiency, HIV, and splenic dysfunctionVery low CH50 and AH50Shared/common pathway defect: C3 or terminal componentsAbsent C6Terminal complement deficiency with recurrent meningococcal risk That pattern is exactly why board questions love this vignette: the microbiology is obvious, but the immunology is the real diagnosis. [\[3\]](#cite-3 "Reference [3]") When he becomes hypotensive --------------------------- Once the blood pressure falls to 85/45 mmHg, this is presumptive septic shock. High-flow oxygen, large-bore IV or IO access, continuous monitoring, and immediate ceftriaxone or cefotaxime should already be underway. Current pediatric Surviving Sepsis Campaign guidance supports 10–20 mL/kg crystalloid boluses, titrated carefully up to 40–60 mL/kg in the first hour with frequent reassessment for perfusion and fluid overload. If hypotension or abnormal perfusion persists, start epinephrine or norepinephrine early; if central access is delayed, peripheral or IO vasoactive infusion is acceptable in experienced hands. If work of breathing rises or mental status declines, intubation may become hemodynamically necessary, and septic shock guidance suggests avoiding etomidate. Keep droplet precautions in place until 24 hours of effective therapy have elapsed, and remember that close contacts and airway-exposed healthcare personnel need chemoprophylaxis regardless of vaccination status. [\[4\]](#cite-4 "Reference [4]") Why CH50 and AH50 both collapse ------------------------------- The laboratory pattern is the teaching point. Low CH50 with low AH50 implies a defect in the shared downstream cascade, classically C3 or C5-C9. When C3 is normal and a specific assay shows absent C6, the problem localizes to the terminal pathway. That matters physiologically because terminal components form the membrane attack complex; without it, serum killing of *Neisseria* is impaired, even if the patient otherwise looks immunologically ordinary between infections. ESID/ERN guidance notes that terminal component deficiencies markedly increase meningococcal risk, and most hereditary complement deficiencies, including terminal pathway defects, are autosomal recessive. Siblings therefore deserve screening with functional complement assays followed by component testing if abnormal. [\[3\]](#cite-3 "Reference [3]") > **Clinical Pearl:** A second episode of invasive *Neisseria* is a complement workup until proven otherwise. Recovery from the first episode does not lower the stakes of the next fever. [\[1\]](#cite-1 "Reference [1]") Prevention after recovery ------------------------- Prevention has to be explicit, current, and written down. For people aged 2 years and older with persistent complement deficiency, CDC recommends a 2-dose **MenACWY** primary series 8 weeks apart, followed by boosters every 5 years while risk persists. **MenB** is also indicated from age 10 in high-risk patients; current CDC guidance uses a 3-dose series at 0, 1–2, and 6 months for those at increased risk, with a booster 1 year after the primary series and every 2–3 years thereafter. MenB products are not interchangeable. As of 2025, age-eligible patients who need MenACWY and MenB on the same day may receive a pentavalent **MenABCWY** product instead. Ensure routine pneumococcal and Hib immunization is current as well, especially if the broader complement phenotype is still being clarified. [\[5\]](#cite-5 "Reference [5]") Board answers often favor penicillin-based long-term prophylaxis. Real practice is slightly grayer: ESID/ERN recommends individualizing continuous prophylaxis, especially for patients with recurrent infections despite vaccination, while making sure every patient has an emergency plan and rapid access to care. For a teenager with proven C6 deficiency and recurrent invasive disease, long-term prophylaxis with ID or immunology follow-up is usually reasonable. The most important discharge step, however, is a fever action plan: any future fever, purpura, or sepsis-like symptom requires immediate assessment, not home observation. [\[6\]](#cite-6 "Reference [6]") Clinical Application -------------------- After stabilization, the next orders should be boring and systematic: send CH50, AH50, and component studies; test for HIV; review medications for complement inhibitors; verify immunization history; notify public health for contact management; and arrange sibling screening before follow-up is lost. Those steps prevent the third episode. [\[2\]](#cite-2 "Reference [2]") Key Points for Board Exams -------------------------- - Recurrent meningococcal disease should prompt evaluation for complement deficiency, HIV, and splenic dysfunction. [\[2\]](#cite-2 "Reference [2]") - Low CH50 plus low AH50 points to C3 or terminal complement defects; absent C6 confirms terminal pathway disease. [\[3\]](#cite-3 "Reference [3]") - Pediatric septic shock management uses 10–20 mL/kg crystalloid boluses with rapid reassessment and early vasoactive support if perfusion remains poor. [\[7\]](#cite-7 "Reference [7]") - High-risk complement-deficient patients need both MenACWY and MenB, with ongoing booster doses while risk persists. [\[5\]](#cite-5 "Reference [5]") - Family screening and a written fever-emergency plan are as important as the inpatient antibiotic course. [\[6\]](#cite-6 "Reference [6]") Conclusion ---------- The memorable part of this case is not the meningitis; it is the recurrence. In pediatrics, a second invasive *Neisseria* episode should permanently change the problem list to include terminal complement deficiency, lifelong vaccine planning, and aggressive safety-netting for every future fever. [\[6\]](#cite-6 "Reference [6]") Frequently Asked Questions ---------------------------- ### How do you interpret a markedly low CH50 and AH50 in this setting? That pattern points to a defect shared by the classical and alternative pathways—most often C3 or a terminal complement component such as C5-C9. Specific component testing then localizes the defect. [\[3\]](#cite-3 "Reference [3]") ### Why does recurrent meningococcal disease so strongly suggest terminal complement deficiency? Terminal complement components form the membrane attack complex needed for effective serum killing of *Neisseria*. Defects in C5-C9 therefore create a disproportionate risk of recurrent invasive meningococcal infection. [\[6\]](#cite-6 "Reference [6]") ### What meningococcal vaccine plan is current for a teenager with persistent complement deficiency? Use MenACWY as a 2-dose primary series 8 weeks apart with boosters every 5 years, plus MenB as a 3-dose series at 0, 1–2, and 6 months with boosters 1 year later and every 2–3 years while risk continues. [\[5\]](#cite-5 "Reference [5]") ### Do asymptomatic siblings need screening? Yes. Terminal complement deficiencies are typically autosomal recessive, and ESID/ERN recommends testing siblings and other potentially affected relatives because they benefit from the same preventive care. [\[6\]](#cite-6 "Reference [6]") ### Is lifelong antibiotic prophylaxis mandatory after C6 deficiency is confirmed? Not universally. Penicillin-based prophylaxis is commonly used and often tested on exams, but guideline-style expert recommendations favor individualized long-term prophylaxis plus a strict emergency fever plan. [\[6\]](#cite-6 "Reference [6]") References (11) ------------------- 1. 1. [ www.cdc.gov/meningococcal/hcp/clinical/index.html ](https://www.cdc.gov/meningococcal/hcp/clinical/index.html) [↩](#cite-ref-1-1 "Back to text") 2. 2. [ www.nice.org.uk/guidance/ng240/resources/meningitis-bacterial-and-meningococcal-disease-recognition-diagnosis-and-management-pdf-66143949881029 ](https://www.nice.org.uk/guidance/ng240/resources/meningitis-bacterial-and-meningococcal-disease-recognition-diagnosis-and-management-pdf-66143949881029) [↩](#cite-ref-2-1 "Back to text") 3. 3. [ www.ncbi.nlm.nih.gov/books/NBK557581 ](https://www.ncbi.nlm.nih.gov/books/NBK557581/) [↩](#cite-ref-3-1 "Back to text") 4. 4. [ www.cdc.gov/meningococcal/hcp/clinical-guidance/index.html ](https://www.cdc.gov/meningococcal/hcp/clinical-guidance/index.html) [↩](#cite-ref-4-1 "Back to text") 5. 5. [ CDC. Meningococcal Vaccination: ACIP Recommendations (2020). ](https://www.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htm) [↩](#cite-ref-5-1 "Back to text") 6. 6. [ Morris C, et al. ESID and ERN RITA Complement Guideline: Deficiencies, Diagnosis, and Management. ](https://link.springer.com/article/10.1007/s10875-020-00754-1) [↩](#cite-ref-6-1 "Back to text") 7. 7. [ www.sccm.org/Clinical-Resources/Guidelines/Guidelines/Surviving-Sepsis-Campaign-International-Guidelines ](https://www.sccm.org/Clinical-Resources/Guidelines/Guidelines/Surviving-Sepsis-Campaign-International-Guidelines) [↩](#cite-ref-7-1 "Back to text") 8. 8. [ CDC. New Dosing Interval and Schedule for the Bexsero MenB-4C Vaccine (2024). ](https://www.cdc.gov/mmwr/volumes/73/wr/mm7349a3.htm) 9. 9. [ CDC. Use of the GSK MenACWY-CRM/MenB-4C Pentavalent Meningococcal Vaccine (2025). ](https://www.cdc.gov/mmwr/volumes/75/wr/mm7501a2.htm) 10. 10. [ Society of Critical Care Medicine. Surviving Sepsis Campaign Guidelines for Children. ](https://www.sccm.org/clinical-resources/guidelines/guidelines/surviving-sepsis-campaign-international-guidelines) 11. 11. [ NICE NG240. Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management. ](https://www.nice.org.uk/guidance/ng240) Keep going Practice Pediatrics the way boards test ----------------------------------------- - Age‑specific differentials and management - Growth, development, and immunizations - Target weak areas with smart review [ Start practicing ](https://mdster.com/user/dashboard) [ Explore Pediatrics ](https://mdster.com/speciality/pediatrics) [ View pricing ](https://mdster.com/pricing) [ Explore features ](https://mdster.com/features) No credit card required. Full access to all features. No commitment. Cancel anytime. Explore topics: [ # Board Review ](https://mdster.com/blog?tag=board-review) [ # Pediatrics ](https://mdster.com/blog?tag=pediatrics) [ # Case Discussion ](https://mdster.com/blog?tag=case-discussion) [ # Infectious Diseases ](https://mdster.com/blog?tag=infectious-diseases) [ # Immunology ](https://mdster.com/blog?tag=immunology) [ Back to all posts ](https://mdster.com/blog) Discussion () ----------------- Join the discussion [ Log in ](https://mdster.com/auth/login) or [ Sign up ](https://mdster.com/auth/register) No comments yet Be the first to share your thoughts! ![]() More in Case Discussion ----------------------- [ See all ](https://mdster.com/blog?category=case-discussion) [### Febrile Neutropenia in Septic Shock: An ED Case Discussion 5 min read Apr 19, 2026 ](https://mdster.com/blog/febrile-neutropenia-in-septic-shock-an-ed-case-discussion) [### Parvovirus B19 and Nonimmune Hydrops: An OB-GYN Case Discussion 6 min read Apr 17, 2026 ](https://mdster.com/blog/parvovirus-b19-and-nonimmune-hydrops-an-ob-gyn-case-discussion) Related Posts ------------- [ ![Structured Differential for FUO, Weight Loss, and Night Sweats](https://mdster.com/storage/blog/images/structured-differential-for-fuo-weight-loss-and-night-sweats.jpg) Medical Education ### Structured Differential for FUO, Weight Loss, and Night Sweats Use a board-ready Family Medicine framework for fever of unknown origin with weight loss and night sweats, organized by system and sharpened by exposures and immunocompromise. 6 min read 0 comments ](https://mdster.com/blog/structured-differential-for-fuo-weight-loss-and-night-sweats) [ ![Febrile Neutropenia in Septic Shock: An ED Case Discussion](https://mdster.com/storage/blog/images/febrile-neutropenia-in-septic-shock-an-ed-case-discussion.jpg) Case Discussion ### Febrile Neutropenia in Septic Shock: An ED Case Discussion A case-based review of neutropenic septic shock in the ED, focusing on ANC calculation, culture technique, early antipseudomonal therapy, vancomycin triggers, and norepinephrine. 5 min read 0 comments ](https://mdster.com/blog/febrile-neutropenia-in-septic-shock-an-ed-case-discussion) [ ![Healthcare-Associated Infection Prevention: CAUTI, CLABSI, VAE](https://mdster.com/storage/blog/images/healthcare-associated-infection-prevention-cauti-clabsi-vae.jpg) Medical Education ### Healthcare-Associated Infection Prevention: CAUTI, CLABSI, VAE A focused, up-to-date review of healthcare-associated infection prevention in Internal Medicine, covering CAUTI, CLABSI bundle concepts, and modern ventilator prevention. 7 min read 0 comments ](https://mdster.com/blog/healthcare-associated-infection-prevention-cauti-clabsi-vae) [ ![Special Education Supports in Pediatrics: IEP vs 504 Basics](https://mdster.com/storage/blog/images/special-education-supports-in-pediatrics-iep-vs-504-basics.jpg) Medical Education ### Special Education Supports in Pediatrics: IEP vs 504 Basics A high-yield pediatrics review of IEPs, 504 plans, ADHD and learning-disorder accommodations, and how clinician letters should support school evaluation. 6 min read 0 comments ](https://mdster.com/blog/special-education-supports-in-pediatrics-iep-vs-504-basics) [ ![Parvovirus B19 and Nonimmune Hydrops: An OB-GYN Case Discussion](https://mdster.com/storage/blog/images/parvovirus-b19-and-nonimmune-hydrops-an-ob-gyn-case-discussion.jpg) Case Discussion ### Parvovirus B19 and Nonimmune Hydrops: An OB-GYN Case Discussion A board-style case discussion on parvovirus B19 in pregnancy, showing how hydrops, elevated MCA-PSV, serology, and fetal transfusion fit together in diagnosing fetal anemia. 6 min read 0 comments ](https://mdster.com/blog/parvovirus-b19-and-nonimmune-hydrops-an-ob-gyn-case-discussion) [ ![Capnography as a Diagnostic Tool: ETCO2 Clues in Anesthesia](https://mdster.com/storage/blog/images/capnography-as-a-diagnostic-tool-etco2-clues-in-anesthesia.jpg) Medical Education ### Capnography as a Diagnostic Tool: ETCO2 Clues in Anesthesia A focused anesthesiology review on reading capnography as a diagnostic signal—using ETCO2 trends and waveform changes to detect low cardiac output, PE, and rebreathing. 6 min read 0 comments ](https://mdster.com/blog/capnography-as-a-diagnostic-tool-etco2-clues-in-anesthesia) [ MDster home ](/ "MDster home") Master your medical exams with evidence-based learning. [ GET IT ON Google Play ](https://play.google.com/store/apps/details?id=com.mdster.app) Platform - [Home](https://mdster.com) - [Features](https://mdster.com/features) - [Pricing](https://mdster.com/pricing) - [About](https://mdster.com/about) Resources - [Blog](https://mdster.com/blog) - [Dashboard](https://mdster.com/user/dashboard) Support - [Contact](https://mdster.com/contact) - [Legal & Policies](https://mdster.com/legal) - [Medical Reviewers](https://mdster.com/medical-reviewers) © 2026 MDster [ ](https://play.google.com/store/apps/details?id=com.mdster.app) [Terms](https://mdster.com/terms) [Privacy](https://mdster.com/privacy) [Editorial](https://mdster.com/editorial-policy) reCAPTCHA Protected by reCAPTCHA. Google [Privacy Policy](https://policies.google.com/privacy) and [Terms of Service](https://policies.google.com/terms) apply. Cookie Consent -------------- We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. [ Terms of Use ](https://mdster.com/terms) & [ Privacy Policy ](https://mdster.com/privacy) Accept